Decoy Therapeutics awarded Chief Scientific Officer Barbara Louise Hibner 4,216 shares at $0 per share on August 31, 2026. The transaction matters to investors because it leaves Hibner with 4,216 shares, defining her reported post-award ownership in the company.
Key Highlights
- Barbara Louise Hibner owned 4,216 Decoy Therapeutics shares after the transaction.
- The award took place on August 31, 2026.
- Decoy Therapeutics awarded Chief Scientific Officer Barbara Louise Hibner 4,216 shares on August 31, 2026.
Decoy Therapeutics Inc. (NASDAQ: DCOY) awarded Chief Scientific Officer Barbara Louise Hibner 4,216 shares at $0 per share. The transaction was recorded under SEC transaction code A.
Award Leaves CSO With 4,216 Shares
Hibner serves as Decoy Therapeutics’ chief scientific officer. The award date was August 31, 2026, and her reported ownership following the transaction was 4,216 shares. The consideration for the shares was $0 per share.
FAQs
Q: How many Decoy Therapeutics shares did Barbara Louise Hibner receive?
A: Decoy Therapeutics awarded Chief Scientific Officer Barbara Louise Hibner 4,216 shares on August 31, 2026. The reported consideration was $0 per share, and her ownership following the award was 4,216 shares.
Q: What was the impact of the Decoy Therapeutics stock award?
A: The award left Barbara Louise Hibner with 4,216 Decoy Therapeutics shares after the transaction. The award date was August 31, 2026.
Q: When did Decoy Therapeutics award the shares?
A: Decoy Therapeutics awarded the shares to Barbara Louise Hibner on August 31, 2026. The transaction was recorded under SEC transaction code A.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.